VB 19055
Alternative Names: VB-19055Latest Information Update: 28 Jan 2026
At a glance
- Originator Zhejiang Anglikang Pharmaceutical
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hypertension
Most Recent Events
- 05 Oct 2025 Phase-I clinical trials in Hypertension (In volunteers) in China (PO) (NCT07254481)